United States - English - NLM (National Library of Medicine)

alvix laboratories, llc - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h) - alternaria alternata 20000 [pnu] in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

axis medical & rehabilitation - 38484 - pressure alleviation pad, air, alternating contact, system - alternating air pressure mattress for prevention of bed sores, for invalid patients

Australia - English - Department of Health (Therapeutic Goods Administration)

carewell health - 63241 - alternating-pressure bed mattress system - alternating-pressure surface with control unit pump, designed to actively alternate air cells and occupant's contact points. distribute or relieve pressure points for comfort and to prevent pressure sores. commonly used for elderly or immobilised patients especially in cases of skin breakdown and/or decubitus ulcers, patients with disabilities, patients of high to very high risk, or patients with low body fat.

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts); allergen extracts 1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts); allergen extracts 10 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) - solution for injection - active: allergen extracts 0.1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct929 - acquired genetic alteration ivds - dna ivd probes intended to be used in genetic testing to provide information about acquired genetic alterations, which may include chromosomal alterations, mutations and/or alterations in gene expression, and which may be used to characterise haematological or solid tumour malignancies and/or provide prognostic information.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct929 - acquired genetic alteration ivds - ivds that are intended to be used in genetic testing to provide information about acquired genetic alterations, which may include chromosomal alterations, mutations and/or alterations in gene expression, and which may be used to characterise haematological or solid tumour malignancies and/or provide prognostic information.

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.01 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) - solution for injection - 0.01 ic/ml - active: allergen extracts 0.01 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Australia - English - Department of Health (Therapeutic Goods Administration)

abacus dx pty ltd - ct929 - acquired genetic alteration ivds - an in vitro medical device intended to be used in genetic testing to provide information about acquired genetic alternations, which may include chromosomal alterations, mutations and/or alterations in gene expression, and which may be used to characterise haematological or solid tumour malignancies and/or provide prognostic information.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - alternaria alternata, quantity: 1 ml/ml (equivalent: alternaria alternata, qty 100 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.